AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02088086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BMI screening
Description: Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
Study NCT02680223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision tinted lenses
Description: Tinted lens for patient with reading difficulty or visual stress
Study NCT02680223 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-beneficial tinted lenses
Description: Tinted lenses that are unlikely to help reading difficulty or visual stress
Study NCT01335568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatocyte Matrix Implant
Description: Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
Study NCT02801097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Study NCT02801097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT01252797 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery (15 Gy)
Description: Group A will start at dose level II: 15 Gy~Group B will start at dose level I: 12 Gy
Study NCT01252797 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (12 Gy)
Description: Group B will start at Dose Level I: 12 Gy
Study NCT03463694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Na Cl solution
Description: \~2.6% NaCl solution prepared from sea salt
Study NCT02234583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg tablet for oral administration
Study NCT01150994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Assessment and Follow-up Telephone Intervention (SAFTI).
Description: Mental health evaluation in ED, followed by Post-ED counseling
Study NCT01543971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TXA127
Description: TXA127 : 300mcg/kg per day for 5 days, injection
Study NCT01543971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen (filgrastim)
Description: Neupogen : 10mcg/kg per day for 5 days, injection
Study NCT01015144 — intervention group
Intervention type: DRUG
Intervention: Tulip
Description: Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
Study NCT02907580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Local educational information
Description: Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
Study NCT02907580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National educational information
Description: Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
Study NCT01578330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Fingolimod 0.5mg orally once a day without food.
Study NCT01924507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP - continuous positive air pressure in patients with sleep apnea
Study NCT01134731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone
Description: 1-5 mg daily (QD)
Study NCT02088086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI reporting
Description: Schools will send a report home to parents that provides their child's height, weight, and BMI results.
Study NCT02088086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness testing
Description: Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
Study NCT01134731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium
Description: 300-1500mg QD
Study NCT02088086 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness testing
Description: Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
Study NCT02248493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study NCT02248493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for paracetamol)
Study NCT01248624 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Early Palliative Care Referral
Description: The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
Study NCT01248624 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Palliative Care Referral
Description: The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
Study NCT00850759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual pedestrian environment
Description: a computer-driven virtual pedestrian environment
Study NCT00850759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: computer and video
Description: various computer-based and video-based programs such as Otto the Auto and WalkSafe
Study NCT02248493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Study NCT02248493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoprofen
Study NCT02248493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
Study NCT02248493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
Study NCT02248493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
Study NCT02248493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
Study NCT01134731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-5 placebo capsules
Study NCT03161093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Solution for injection in pre-filled syringe
Study NCT02963220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-AR
Description: 20-30 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
Study NCT01501630 — intervention group
Intervention type: DEVICE
Intervention: performance of PET/CT and whole-body MRI
Description: For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
Study NCT00741754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthrinse with HcT20
Description: Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
Study NCT02964650 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalised rate-response settings
Description: Rate response range fixed to limits suggested by force-frequency curve
Study NCT00603512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg BID, 3 blinded tablets administered BID for 12 weeks
Study NCT00603512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg BID, 3 blinded tablets administered BID for 12 weeks
Study NCT00603512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 1 mg BID, 3 blinded tablets administered BID for 12 weeks
Study NCT03161093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Pharmaceutical form: Capsule
Study NCT03161093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab-matching placebo
Description: Solution for injection in pre-filled syringe
Study NCT03161093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen-matching placebo
Description: Capsule
Study NCT00751166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
Study NCT00751166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
Study NCT00850759 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: streetside training
Description: one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
Study NCT01849250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: Given PO
Study NCT01849250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03639883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal injection
Study NCT00868231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg bid
Description: Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
Study NCT00603512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 3 mg BID, 3 blinded tablets administered BID for 12 weeks
Study NCT00603512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5 mg BID, 3 blinded tablets administered BID for 12 weeks
Study NCT04263233 — intervention group
Intervention type: OTHER
Intervention: Analysis using descriptive statistics of patient clinical outcomes.
Description: Evaluation of the following:~* Laboratory values at admission, week 4, and day 90.~* Pre and post blood pressure at week one and week 4.~* Intradialytic hypotension at week one and week 4.~* Ultrafiltration rates at week one, week 4, day 90, day 180, and day 360.~* Target weight defined and achievement in week one and week 4 and changes between week one and week 4.~* Dialysis access type at week one and day 90.~* Hospitalization and mortality rates.
Study NCT04263233 — intervention group
Intervention type: OTHER
Intervention: Surveys with participants using validated survey tools.
Description: Surveys will assess participants' Symptom index, Quality of Life, Patient Activation as well as satisfaction with the program.
Study NCT04263233 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.
Description: Data will be collected using tracking tools throughout the program.
Study NCT02221817 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trochanter bursa injections
Study NCT02221817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trochanter bursa injections
Study NCT02221817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT03537911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Support Program
Description: Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
Study NCT00091286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine
Study NCT04556123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy
Description: The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.
Study NCT04556123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of the hydration state and decongestive treatment according to clinical judgement alone
Description: Clinical judgement will be performed in each center by a reference physician or nurse
Study NCT04181164 — intervention group
Intervention type: OTHER
Intervention: Microindentation
Description: Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
Study NCT04181164 — intervention group
Intervention type: OTHER
Intervention: High resolution peripheral quantitative computed tomography (HRpQCT)
Description: HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
Study NCT04181164 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biochemical analysis of different bone markers.
Description: Measurement of different bone markers by biochemical analysis of blood samples.
Study NCT01231373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polidocanol injectable foam, 0.125%
Description: active placebo for blinding
Study NCT01231373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polidocanol injectable foam, 0.5%
Description: 0.5% polidocanol foam injection
Study NCT00751166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once daily for 28 days
Study NCT01298310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: 1 mg/mL solution for injection
Study NCT01298310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: 10 mg/mL solution for injection
Study NCT01298310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for injection
Study NCT02927327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero Echo Time (ZTE) scan for head attenuation
Description: The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC
Study NCT00868231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 μg once-daily
Description: Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
Study NCT00456963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: total fat \< 5%, saturated fat \< 10%, vegetables, fruit
Study NCT00456963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: total fat \< 5%, saturated fat \< 10%, vegetables, fruit
Study NCT00456963 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: total fat \< 5%, saturated fat \< 10%, vegetables, fruit
Study NCT00456963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate exercise
Description: 30 min at least 5 times/week
Study NCT00456963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: 30 min at least 5 times/week
Study NCT00456963 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Moderate exercise
Description: 30 min at least 5 times/week
Study NCT00456963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enalapril tablets
Description: one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
Study NCT00456963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
Study NCT00456963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan Tablets
Description: one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
Study NCT00367640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 IR grass pollen allergen extract tablet
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study NCT00367640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 IR grass pollen allergen extract tablet
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study NCT00367640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 IR grass pollen allergen extract tablet
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season
Study NCT02684162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocytes
Description: Given IV
Study NCT02684162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Given SC
Study NCT02684162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01323374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Study NCT01323374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa
Description: Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
Study NCT01323374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa/carbidopa
Description: Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
Study NCT00868231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
Study NCT02927327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q.Static (Q. MRAC) for respiratory motion correction
Description: An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)
Study NCT03267303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-091 5mg
Description: Orally taken once daily for 3 weeks
Study NCT03267303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-091 10mg
Description: Orally taken once daily for 3 weeks
Study NCT03267303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally taken once daily for 3 weeks
Study NCT03120676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
Study NCT01323374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, placebo TID
Study NCT01498380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease \< 20% or blood pressure decrease/increase \< 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease >/= 20% or SBP/DBP/MAP decrease or increase >/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
Study NCT01044459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide 200 µg
Description: aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
Study NCT01044459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide 400 µg
Description: aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
Study NCT02430714 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: 24mg once daily oral dosing to Unresectable thyroid cancer patients
Study NCT00944840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP plus amodiaquine
Description: SP plus amodiaquine or placebo at monthly interval during September, October and November
Study NCT00367640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: One sublingual tablet daily during 4 months before pollen season and during pollen season